 A Message From Traders Agency On April 13th, 2024, I sent my members an email. I told them gold had broken its ceiling… And that what comes next could be the most lucrative gold supercycle in history. Since then, gold has more than doubled. But here’s the part most investors miss: It’s not gold that makes the real money in these cycles. It’s an overlooked “backdoor” asset that leverages the move… And has seen gains of 846%, 1,668%, and 1,915% in past cycles. Based on everything I’m seeing, this cycle could be even bigger… And we’re still in the early stages. If you want to make the most of it, the time to get positioned is NOW…. Here’s the number-one move I recommend making today. Regards,
Ross Givens
Director of Research, Traders Agency
Exclusive Story
Aeluma’s Selloff Could Be Setting Up Its Next Big MoveAuthor: Thomas Hughes. Published: 9/17/2026. 
Key Points
- Aeluma's stock fell after fiscal 2026 earnings showed wider losses and accelerated spending, but the company remains well capitalized with more than $56 million on hand.
- The company is transitioning toward scalable manufacturing of its patented photonic wafer technology, with CHIPS funding, government contracts, and engineering deals signaling accelerating commercialization.
- Analysts rate Aeluma a Moderate Buy with a $25 consensus target, and rising institutional buying alongside high short interest could fuel a rebound or short squeeze.
- Special Report: The Rumors About Elon’s Next Move Are Spreading Fast
Aeluma’s (NASDAQ: ALMU) stock price is under pressure in 2026 because the market has little appetite for risky, cash-burning startups without meaningful revenue. However, Aeluma is not a run-of-the-mill startup, and a catalyst is emerging that investors can capitalize on. The company is in the midst of a major transition, moving from research, development and niche production to the scalable manufacturing of advanced photonic equipment.
Photonics is critical to many advancing technologies, not just AI. It enables faster speeds, greater bandwidth and improved reliability compared with copper wiring, particularly in rugged or high-power applications such as data centers, aerospace, space, industrial equipment, robotics and quantum computing. Highlights from fiscal 2026 indicate that Aeluma’s timeline for commercialization is accelerating. These highlights include the company’s intent to claim $30 million in CHIPS funding, $5.3 million in recently awarded government development contracts, an expanded leadership team and advancing discussions for non-recurring engineering agreements. Non-recurring engineering agreements may not sound particularly exciting, but they can generate millions of dollars in revenue, validate the technology, lead to follow-on orders and broaden demand. Follow-on orders matter most because they result from engineering design wins, locking the company’s photonic devices into long-term product cycles. Aeluma Reduces Costs and Improves Performance for ClientsAeluma’s technology is worth watching because it could significantly disrupt the photonic industry. Current standards include “gluing” photonic components onto a silicon wafer substrate. Although this approach gets the job done, it creates hurdles, including misalignment and signal degradation across the interface. Aeluma’s patented technology “grows” photonic materials directly onto the substrate, creating a two-sided wafer. Aeluma’s process enables larger manufacturing volumes, reduces the number of manufacturing steps and produces a wafer that can pass through traditional foundry equipment without specialized tools. This means greater efficiency from the outset: more wafers at a lower cost, with less waste, fewer errors and greater capacity to transfer optical input to silicon circuits. Aeluma has what the semiconductor industry needs; what remains is product validation and the capacity to scale. Aeluma Plunges After Earnings Are ReleasedAeluma did not provide a bullish catalyst in its Q4 fiscal 2026 (FY2026) earnings report, and it was unlikely to. The market wants a contract win and meaningful revenue, which are more likely to arrive in Q1 or Q2 of FY2027. Instead, Aeluma announced accelerated spending and wider losses, an unpopular combination in today’s market. Even so, the spending is focused on team expansion, go-to-market efforts and capacity, all of which align with the accelerating commercialization timeline. Looking ahead, spending is expected to continue accelerating. The company forecasts approximately $11 million in capital expenditures on top of operating costs, compared with last year’s $9.1 million net loss. The key takeaway is that the balance sheet appears well capitalized, with more than $56 million on the books. This should be sufficient for the foreseeable future and could carry the company through to commercialization. As it stands, analysts expect revenue to ramp slowly over the next four quarters before accelerating at a hyper, triple-digit pace in fiscal 2028. Analysts and Institutions Signal Confidence in AelumaAnalysts and institutions reflect optimism about Aeluma’s opportunity, if not an outright bullish stance. MarketBeat tracks only four analysts with current coverage but rates the stock a Moderate Buy, with a 75% Buy-side bias. Coverage and price targets have remained fairly steady over the past year, including some activity over the summer. The critical takeaway is the triple-digit upside forecast and improving institutional holdings. Institutional-quality investors, including insiders, corporations, funds and private capital, own approximately half of the floating shares and increased their buying in early Q3. The likely outcome is that this group will provide a price floor near $11, as it has in the past. The Risks Are Real, But the Selloff Looks Like a BottomRisks include short interest and dilution. The company’s lack of revenue, cash burn and dilutive actions have triggered short selling, lifting short interest into the 20% range in early September. The offset is that dilution is a diminishing risk and unlikely in the near term, given the company’s balance sheet. A contract win could also trigger short covering. In this scenario, institutions may also buy aggressively, leading to a short squeeze and a sharp rise in the share price. A move to the consensus target of $25 would be a stepping stone toward even higher prices and new all-time highs. 
As bad as ALMU’s post-release plunge seems, the move is not entirely bearish. It reflects market capitulation and the potential formation of a bottom. Price action gapped lower at the open, set a new low and then moved higher from those lows, revealing support at a critical level. The likely outcome is that ALMU establishes a support base and rebounds, potentially very quickly, as it has in the past.
This ad is sent on behalf of Traders Agency, LLC, at 20 N Orange Ave Suite 1100, Orlando, FL 32801. If you’re not interested in this opportunity from Traders Agency, LLC, please click here to remove your email from these offers.
This ad is sent on behalf of Traders Agency, LLC, at 20 N Orange Ave Suite 1100, Orlando, FL 32801. If you’re not interested in this opportunity from Traders Agency, LLC, please click here to remove your email from these offers.
. |
